A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

NCT04024761 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes
Myeloproliferative Neoplasm
Juvenile Myelomonocytic Leukemia

Interventions

BIOLOGICAL: CIML NK
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]